Editas Medicine cleared for first human gene-editing trial
Australian authorities cleared Editas Medicine’s experimental gene-editing treatment for its first human clinical trial, with EDIT shares up about 4.7% before paring gains.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.